AAS members and colleagues are invited to this
pre-IVBM Satellite Meeting
Sunday, 6 September 2026 10:00AM - 2:30PM
South Australian Health and Medical Research Institute (SAHMRI), Adelaide
No registration fee, but ...Everyone does need to register!
Click the "yes" button and follow the prompts.
You will receive a confirmation.
All abstracts have been accepted for oral presentation.
The abstracts are currently undergoing evaluation,
and the specific presentation category
(Rising Star Awards or Flash Talks)
will be communicated in late July 2026.
CURRENT PROGRAM
10:00am – 10:30am: A/Prof Jeffrey Kroon, Amsterdam UMC, Netherlands
10:30am – 11:30am: Rapid Fire Flash Talks (3 minutes per presenter)
11:30am – 12:15pm: ECR Rising Star Presentations
12:15pm – 1:15pm: Lunch
1:15pm – 2:00pm: HDR Rising Star Presentations
2:00pm – 2:30pm: Prof Judy de Haan, Baker Heart and Diabetes Institute, Australia
AAS 2026 RISING STARS AND RAPID FIRE FLASH TALKS
The following people will be presenting their latest research: timings and session selection to be advised late July. Please come along to support and learn from them, and to mingle with like-minded colleagues.
Presenters: if you are from outside SA, don't forget you may apply for an AAS Trust Travel Grant. Closing date July 10. Click here to check the application criteria and apply via the member portal
| First name |
Last name |
State |
Abstract |
| Afreen |
|
SA |
Diroximel Fumarate-loaded porphyrin lipid nanoparticles as novel anti-inflammatory and antioxidant agents to inhibit atherosclerosis |
| Marziyeh |
Anari |
VIC |
Gut Microbiota-Targeted Therapy with Akkermansia muciniphila: Live versus Pasteurised Formulations in Atherosclerotic Plaque Stabilisation |
| Chloe |
Bourchier |
VIC |
Investigating the role of TREML4 in the progression of atherosclerosis |
| Demeke Geremew |
Debebe |
SA |
Deletion of the asialoglycoprotein receptor 1 (ASGR1) has atheroprotective effects with improved macrophage lipid handling and immune cell regulation |
| Shevin |
Fernando |
VIC |
RIPK1 Rewired: Driving Phenotypic Switching, Inflammation, and Necroptosis in Atherogenic VSMCs |
| Samuel |
Hansen |
NSW |
Comprehensively Evaluating the Biocompatibility of Zn-Cu-Li alloys for the Development of Bioresorbable Cardiovascular Stents |
| Rakila |
Kurugalage |
SA |
Association Between Lipoprotein(a) and Coronary Plaque Burden and Progression on Coronary Computed Tomography Angiography: A Systematic Review and Meta-analysis |
| Natalie |
Le |
NSW |
Does lower-limb ischaemia impact cardiac health? A pilot study. |
| Jiandi |
Liu |
SA |
Proteomic and Lipidomic Profiling of In-Stent Neoatherosclerosis Using a Novel Murine Model |
| Sanuri |
Liyanage |
SA |
Yolk Sac-Derived Endothelial-Macrophage Progenitors in Skin: Drivers of Wound Healing and Tumour Growth |
| Karen |
Lye |
NSW |
Australian Native Plant Extracts as Modulators of Early Atherosclerotic Inflammation and Oxidative Stress |
| Sanchia Marie |
Malapitan |
QLD |
Nanomedicine for atherosclerosis: Development of silica nanoparticles for proteoglycan-specific targeting and imaging in the vessel wall. |
| Victoria |
Nankivell |
SA |
Diroximel fumarate has atheroprotective and plaque-stabilizing effects in the tandem stenosis mouse model of plaque instability |
| Tien |
Nguyen |
VIC |
Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes |
| Rajesh |
Pathy |
SA |
Raised lipoprotein(a) associates with rapidly progressive coronary atherosclerosis after acute coronary syndrome |
| Namrata |
Prajapati |
VIC |
4-Octyl-Itaconate Attenuates Inflammation and Lipidomic Remodeling through the Nrf2–NLRP3 Axis in Activated Macrophages |
| Shayesteh |
Shahriary |
NSW |
Comparative Effects of Bushfire-Derived Particulate Matter of Different Sizes on Endothelial Dysfunction |
| Emma |
Solly |
SA |
Hypoxia-Targeted Nanoparticle Delivery of AntimiR-181c Rescues Diabetes-Impaired Angiogenesis and Wound Healing |
| Liam |
Stretton |
SA |
Asgr1-silencing lipid-based nanoparticles improve macrophage efflux capacity and reduce inflammatory mediators |
| Seyed Saeed |
Tamehri Zadeh |
WA |
European and Canadian derived risk prediction equations for atherosclerotic cardiovascular disease are valid in Australian patients with genetically confirmed familial hypercholesterolaemia |
| Caitlin |
Vella |
VIC |
Enhancing efferocytosis with BELMO reduces atherosclerotic plaque burden |
| Ziyang (Alex) |
Zhang |
VIC |
Investigating Immune Cell Polyunsaturated Fatty Acid–Containing Lipid Metabolism and Ferroptosis-Associated Features During Atherosclerosis Progression |
If you have any questions, please contact us at learn@athero.org.au.
Following this, we warmly invite all atherosclerosis researchers to attend the 2026 International Vascular Biology Meeting (IVBM) at the Adelaide Convention Centre where we have organised a society discount on registration.
IVBM 2026
6 – 10 September 2026 Adelaide Convention Centre
Visit ivbm2026.com for more information.
